INDUCTION OF HYPORESPONSIVENESS TO FULLY ALLOGENEIC CARDIAC GRAFTS BY INTRATRACHEAL DELIVERY OF ALLOANTIGEN1

Background. Soluble protein delivered through the mucosal surface can induce immunological unresponsiveness. The purpose of this study was to determine if prior exposure to alloantigen via the trachea could modulate the immune response to subsequent cardiac allografts. Methods. Hearts from C57BL/10(H2b) mice were transplanted into CBA(H2k) recipients. Recipient mice were given donor 1×107 splenocytes into the trachea with or without antibody specific for mouse CD80 (1G10) and/or CD86 (GL1) (100 &mgr;g each) 7 days before transplantation. Results. All grafts survived in recipients treated with intratracheal delivery of alloantigen for over 35 days (mean survival time [MST], 56 days), whereas naive control mice and mice treated with syngeneic antigen rejected grafts acutely (MST, 8 and 7 days, respectively). Interestingly, when 1G10, GL1, or both of them were combined with the protocol, the majority of grafts were rejected within 21 days after grafting (MST, 7, 15, and 17 days, respectively). Conclusion. Intratracheal delivery of alloantigen induced significantly prolonged survival of fully mismatched cardiac allografts and the effect was abrogated by the blockade CD80 and/or CD86 pathway.

[1]  J. Ringers,et al.  Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. , 1999, Transplantation.

[2]  S. Lederman,et al.  Antigen presenting cells integrate opposing signals from CD4+ and CD8+ regulatory T lymphocytes to arbitrate the outcomes of immune responses. , 1999, Human immunology.

[3]  T. Strom,et al.  CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. , 1999, Journal of immunology.

[4]  H. Weiner,et al.  CTLA-4 is required for the induction of high dose oral tolerance. , 1998, International immunology.

[5]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[6]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[7]  K. Okumura,et al.  Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. , 1996, Transplantation proceedings.

[8]  R. Holmdahl,et al.  Mucosal tolerance and suppression of collagen‐induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184‐198 of bovine type II collagen (CII) expressing a dominant T cell epitope , 1996, Clinical and experimental immunology.

[9]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[10]  R. O’Hehir,et al.  Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice , 1993, The Journal of experimental medicine.

[11]  H. Weiner,et al.  Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. , 1993, Transplantation.

[12]  H. Weiner,et al.  DOWN‐REGULATION OF THE IMMUNE RESPONSE TO HISTOCOMPATIBILITY ANTIGENS AND PREVENTION OF SENSITIZATION BY SKIN ALLOGRAFTS BY ORALLY ADMINISTERED ALLOANTIGEN1 , 1992, Transplantation.

[13]  H. Weiner,et al.  Antigen-driven bystander suppression after oral administration of antigens , 1991, The Journal of experimental medicine.